Sökning: WFRF:(Shankar K.) > Global Cardiovascul...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 06628naa a2201585 4500 | |
001 | oai:gup.ub.gu.se/255568 | |
003 | SwePub | |
008 | 240528s2017 | |||||||||||000 ||eng| | |
024 | 7 | a https://gup.ub.gu.se/publication/2555682 URI |
024 | 7 | a https://doi.org/10.1681/asn.20160505622 DOI |
040 | a (SwePub)gu | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Thomas, B.4 aut |
245 | 1 0 | a Global Cardiovascular and Renal Outcomes of Reduced GFR |
264 | c 2017-04-13 | |
264 | 1 | b Ovid Technologies (Wolters Kluwer Health),c 2017 |
520 | a The burden of premature death and health loss from ESRD is well described. Less is known regarding the burden of cardiovascular disease attributable to reduced GFR. We estimated the prevalence of reduced GFR categories 3, 4, and 5 (not on RRT) for 188 countries at six time points from 1990 to 2013. Relative risks of cardiovascular outcomes by three categories of reduced GFR were calculated by pooled random effects meta-analysis. Results are presented as deaths for outcomes of cardiovascular disease and ESRD and as disability-adjusted life years for outcomes of cardiovascular disease, GFR categories 3, 4, and 5, and ESRD. In 2013, reduced GFR was associated with 4% of deaths worldwide, or 2.2 million deaths (95% uncertainty interval [95% UI], 2.0 to 2.4 million). More than half of these attributable deaths were cardiovascular deaths (1.2 million; 95% UI, 1.1 to 1.4 million), whereas 0.96 million (95% UI, 0.81 to 1.0 million) were ESRD-related deaths. Compared with metabolic risk factors, reduced GFR ranked below high systolic BP, high body mass index, and high fasting plasma glucose, and similarly with high total cholesterol as a risk factor for disability-adjusted life years in both developed and developing world regions. In conclusion, by 2013, cardiovascular deaths attributed to reduced GFR outnumbered ESRD deaths throughout the world. Studies are needed to evaluate the benefit of early detection of CKD and treatment to decrease these deaths. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicin0 (SwePub)3022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicine0 (SwePub)3022 hsv//eng |
653 | a chronic kidney-disease | |
653 | a glomerular-filtration-rate | |
653 | a collaborative | |
653 | a metaanalysis | |
653 | a mesoamerican nephropathy | |
653 | a maintenance dialysis | |
653 | a population | |
653 | a cohorts | |
653 | a general-population | |
653 | a heart-disease | |
653 | a all-cause | |
653 | a risk | |
653 | a Urology & Nephrology | |
653 | a ettine.os | |
653 | a 1974 | |
653 | a american journal of epidemiology | |
653 | a v99 | |
653 | a p325 | |
700 | 1 | a Matsushita, K.4 aut |
700 | 1 | a Abate, K. H.4 aut |
700 | 1 | a Al-Aly, Z.4 aut |
700 | 1 | a Amlov, J.4 aut |
700 | 1 | a Asayama, K.4 aut |
700 | 1 | a Atkins, R.4 aut |
700 | 1 | a Badawi, A.4 aut |
700 | 1 | a Ballew, S. H.4 aut |
700 | 1 | a Banerjee, A.4 aut |
700 | 1 | a Barregård, Lars,d 1948u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för samhällsmedicin och folkhälsa,Institute of Medicine, School of Public Health and Community Medicine4 aut0 (Swepub:gu)xbarrl |
700 | 1 | a Barrett-Connor, E.4 aut |
700 | 1 | a Basu, S.4 aut |
700 | 1 | a Bello, A. K.4 aut |
700 | 1 | a Bensenor, I.4 aut |
700 | 1 | a Bergstrom, J.4 aut |
700 | 1 | a Bikbov, B.4 aut |
700 | 1 | a Blosser, C.4 aut |
700 | 1 | a Brenner, H.4 aut |
700 | 1 | a Carrero, J. J.4 aut |
700 | 1 | a Chadban, S.4 aut |
700 | 1 | a Cirillo, M.4 aut |
700 | 1 | a Cortinovis, M.4 aut |
700 | 1 | a Courville, K.4 aut |
700 | 1 | a Dandona, L.4 aut |
700 | 1 | a Dandona, R.4 aut |
700 | 1 | a Estep, K.4 aut |
700 | 1 | a Fernandes, J.4 aut |
700 | 1 | a Fischer, F.4 aut |
700 | 1 | a Fox, C.4 aut |
700 | 1 | a Gansevoort, R. T.4 aut |
700 | 1 | a Gona, P. N.4 aut |
700 | 1 | a Gutierrez, O. M.4 aut |
700 | 1 | a Hamidi, S.4 aut |
700 | 1 | a Hanson, S. W.4 aut |
700 | 1 | a Himmelfarb, J.4 aut |
700 | 1 | a Jassal, S. K.4 aut |
700 | 1 | a Jee, S. H.4 aut |
700 | 1 | a Jha, V.4 aut |
700 | 1 | a Jimenez-Corona, A.4 aut |
700 | 1 | a Jonas, J. B.4 aut |
700 | 1 | a Kengne, A. P.4 aut |
700 | 1 | a Khader, Y.4 aut |
700 | 1 | a Khang, Y. H.4 aut |
700 | 1 | a Kim, Y. J.4 aut |
700 | 1 | a Klein, B.4 aut |
700 | 1 | a Klein, R.4 aut |
700 | 1 | a Kokubo, Y.4 aut |
700 | 1 | a Kolte, D.4 aut |
700 | 1 | a Lee, K.4 aut |
700 | 1 | a Levey, A. S.4 aut |
700 | 1 | a Li, Y. M.4 aut |
700 | 1 | a Lotufo, P.4 aut |
700 | 1 | a Abd El Razek, H. M.4 aut |
700 | 1 | a Mendoza, W.4 aut |
700 | 1 | a Metoki, H.4 aut |
700 | 1 | a Mok, Y.4 aut |
700 | 1 | a Muraki, I.4 aut |
700 | 1 | a Muntner, P. M.4 aut |
700 | 1 | a Noda, H.4 aut |
700 | 1 | a Ohkubo, T.4 aut |
700 | 1 | a Ortiz, A.4 aut |
700 | 1 | a Perico, N.4 aut |
700 | 1 | a Polkinghorne, K.4 aut |
700 | 1 | a Al-Radaddi, R.4 aut |
700 | 1 | a Remuzzi, G.4 aut |
700 | 1 | a Roth, G.4 aut |
700 | 1 | a Rothenbacher, D.4 aut |
700 | 1 | a Satoh, M.4 aut |
700 | 1 | a Saum, K. U.4 aut |
700 | 1 | a Sawhney, M.4 aut |
700 | 1 | a Schottker, B.4 aut |
700 | 1 | a Shankar, A.4 aut |
700 | 1 | a Shlipak, M.4 aut |
700 | 1 | a Silva, D. A. S.4 aut |
700 | 1 | a Toyoshima, H.4 aut |
700 | 1 | a Ukwaja, K.4 aut |
700 | 1 | a Umesawa, M.4 aut |
700 | 1 | a Vollset, S. E.4 aut |
700 | 1 | a Warnock, D. G.4 aut |
700 | 1 | a Werdecker, A.4 aut |
700 | 1 | a Yamagishi, K.4 aut |
700 | 1 | a Yano, Y.4 aut |
700 | 1 | a Yonemoto, N.4 aut |
700 | 1 | a Zaki, M. E.4 aut |
700 | 1 | a Naghavi, M.4 aut |
700 | 1 | a Forouzanfar, M. H.4 aut |
700 | 1 | a Murray, C. J. L.4 aut |
700 | 1 | a Coresh, J.4 aut |
700 | 1 | a Vos, T.4 aut |
700 | 1 | a Global Burden Dis, G. F. R. Collabo C. K. D. Prognosis Consortium Global Burden Dis Genitourinary Ex4 aut |
710 | 2 | a Göteborgs universitetb Institutionen för medicin, avdelningen för samhällsmedicin och folkhälsa4 org |
773 | 0 | t Journal of the American Society of Nephrologyd : Ovid Technologies (Wolters Kluwer Health)g 28:7, s. 2167-2179q 28:7<2167-2179x 1046-6673x 1533-3450 |
856 | 4 | u https://jasn.asnjournals.org/content/jnephrol/28/7/2167.full.pdf |
856 | 4 8 | u https://gup.ub.gu.se/publication/255568 |
856 | 4 8 | u https://doi.org/10.1681/asn.2016050562 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy